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The large Rep proteins Rep78 and Rep68 of the helper-dependent adeno associated virus type 2 (AAV-2) are essential for both site-
specific integration of AAV DNA in the absence of helpervirus and productive AAV replication in the presence of helpervirus. We have
identified UBC9, the E2 conjugating enzyme for the small ubiquitin-related polypeptide SUMO-1, as binding partner of the large Rep
proteins in yeast two-hybrid analysis and in GST pulldown assays. Modification of the large Rep proteins with SUMO-1 could be
demonstrated in immunoblot analysis and in immunoprecipitations, with the lysine residue at amino acid position 84 serving as the major
attachment site. The largely sumolation-deficient Rep78 lysine to arginine point mutant showed a strongly reduced half-life as compared to
the wild-type protein. This finding implicates a role for sumolation in the regulation of Rep78 protein stability that is assumed to be critical
for the establishment and maintenance of AAV latency.
D 2004 Elsevier Inc. All rights reserved.
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Adeno associated virus type 2 (AAV-2) is a human
parvovirus that has been assigned to the genusDependovirus
because it typically relies on a coinfecting helpervirus such as
adenovirus or herpes virus for productive replication (Berns
and Linden, 1995). Infection in the absence of helpervirus
usually results in a latent state of AAV-2 by site-specific
integration of the viral DNA into human chromosome 19
(Samulski, 1993). The integrated provirus can then be
reactivated by superinfection with a helpervirus (Berns and
Linden, 1995).
The coding region of the 4.7-kb single-stranded AAV-2
DNA genome (Srivastava et al., 1983) is flanked by two 145-
base-pair inverted terminal repeats (ITRs) and consists of two
open reading frames, rep and cap. Cap encodes the three0042-6822/$ - see front matter D 2004 Elsevier Inc. All rights reserved.
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E-mail address: stefan.weger@charite.de (S. Weger).structural proteins VP1, VP2, and VP3 (Becerra et al., 1988;
Cassinotti et al., 1988) expressed from a promoter located at
map position 40 (p40). Rep encodes four overlapping
regulatory (Rep) proteins (Mendelson et al., 1986), which
are expressed from two promoters located at map positions 5
(p5) and 19 (p19). The p5 promoter initiates the unspliced and
the single-spliced transcripts encoding the large Rep proteins
Rep78 and Rep68, respectively. These are essential for AAV-
2 DNA replication in the presence of helpervirus (Hermonat
et al., 1984; Tratschin et al., 1984) and site-specific
integration in the absence of helpervirus (Balague et al.,
1997; Samulski, 1993;Weitzman et al., 1994). Both functions
involve ATP-dependent helicase, site- and strand-specific
endonuclease, and sequence-specific DNA binding activities
of Rep78 and Rep68 (Im and Muzyczka, 1990, 1992). The
p19 proteins Rep52 and Rep40 lack the 224 amino terminal
residues of Rep78 and Rep68 involved in site-specific DNA
binding (Owens et al., 1993). Through complex formation
with Rep78 and Rep68 (Dubielzig et al., 1999), they mediate
the translocation of the single-stranded AAV progeny DNA
into the preformed capsid (King et al., 2001).04) 284–294
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promoters in the absence of helpervirus (Horer et al.,
1995; Kyostio et al., 1994; Trempe and Carter, 1988), they
activate the p19 and the p40 promoters after coinfection
with adenovirus. This activation depends upon the Rep
binding sites in the ITRs (ITR-RBS) and the p5 promoter as
well as additional elements in the p19 and p40 promoters
(McCarty et al., 1991; Pereira and Muzyczka, 1997a,
1997b; Pereira et al., 1997; Weger et al., 1997). The p5
promoter is both activated by Rep78/Rep68 in the presence
of adenovirus mediated by the ITR-RBS and repressed by
Rep78/Rep68 mediated by the p5RBS (Pereira et al., 1997).
The Rep proteins can bind to a variety of cellular
proteins. Interaction of Rep78 and Rep68 with the tran-
scription factor Sp1 is involved in the activation of p19 and
p40 gene expression in the presence of adenovirus (Pereira
and Muzyczka, 1997b). Through their C-terminal domain,
Rep78 and Rep52 interact with and inhibit cAMP-depend-
ent protein kinase A (PKA) and its homolog PrKX
(Chiorini et al., 1998). The Rep78/Rep52 mediated
decrease in PKA activity inhibits adenovirus replication
and is necessary to preserve AAV2 replication fitness
during an Ad co-infection (Di Pasquale and Chiorini,
2003). Other cellular interaction partners of the Rep
proteins include the high-mobility chromosomal protein
HMG1 (Costello et al., 1997), the TATA box binding
protein TBP (Hermonat et al., 1998), the tumor suppressor
protein p53 (Batchu et al., 1999), the transcriptional
coactivator PC4 (Weger et al., 1999), and the topoisomerase
I binding RS-rich protein Topors (Weger et al., 2002).
Not much is known yet about posttranslational modifi-
cations of the AAV Rep proteins, which might regulate their
enzymatic activities and their interaction with cellular
proteins. All four Rep proteins have been found to be
phosphorylated at serine residues after AAV/adenovirus
coinfection (Collaco et al., 1997) and hyper-phosphoryla-
tion of the Rep78 protein inhibits its binding to the AAV
terminal repeats and its helicase activity in vitro (Narasim-
han et al., 2002). The phosphorylation of Rep68 at serine
residue 535 is critical for its association with 14-3-3 proteins
q and g (Han et al., 2004).
Small ubiquitin-like modifier (SUMO) proteins are
ubiquitously expressed in eukaryotic cells and covalently
attached to a variety of cellular and viral proteins through the
E1-activating enzyme Aos1/Uba2 and the E2-conjugating
enzyme Ubc9 (Melchior, 2000; Muller et al., 2001). Several
E3 ligases, which enhance sumolation of specific target
proteins, have been identified recently (Johnson and Gupta,
2001; Kahyo et al., 2001; Sachdev et al., 2001; Schmidt and
Muller, 2002). Sumolation has been shown to modulate
protein–DNA or protein–protein interactions to alter the
intracellular localization of the target protein or to protect it
from ubiquitin-mediated degradation (Melchior, 2000).
In this study, we report the identification of the human
SUMO-1-conjugating E2 enzyme UBC9 as an interaction
partner of the large Rep proteins Rep78 and Rep68.Furthermore, we demonstrate the covalent modification of
the large Rep proteins by SUMO-1 in vivo, with the lysine
residue at amino acid position 84 as the major SUMO-1
attachment site. The strongly reduced half-life observed for
a largely sumolation-deficient mutant Rep78 protein sug-
gests a critical role for SUMO-1 modification in the
regulation of the stability of the large Rep proteins.Results
Rep68 interacts with the SUMO-1-conjugating enzyme
UBC9 protein in the yeast-two hybrid system
We have previously identified the transcriptional coac-
tivator PC4 and a DNA Topoisomerase I binding Protein
named Topors (for topoisomerase I-binding RS protein) as
interaction partners of the large nonstructural AAV-2
proteins Rep78 and Rep68 in yeast based two-hybrid
screens (Weger et al., 1997, 2002). In one of these screens
with a construct harboring Rep amino acids 172–530
(M172/520, Fig. 1A) as bait and a target library from
noninfected HeLa cells, two additional positive clones were
identified. Both contained the complete open reading frame
of UBC9 (human ubiquitin conjugating enzyme 9). UBC9
alone did not activate reporter gene expression in yeast in
the absence of the bait protein. UBC9 is comprised of 158
amino acids and functions as an E2 enzyme in the
conjugation of the SUMO (small ubiquitin like modifier)
family of proteins to cellular and viral target proteins
(Johnson and Blobel, 1997; Schwarz et al., 1998; Tatham et
al., 2001). We analyzed the Rep domains involved in
interaction with UBC9 in more detail (Fig. 1B). While the
first 172 amino acids of the large Rep proteins were not
required, deletion of Rep amino acids 172–224 abolished
the interaction (Fig. 1B, compare M172/530 and Rep40).
Rep amino acid residues 482–530 were dispensable for
Rep–UBC9 interaction (Fig. 1B, M1/481). Deletion of
further carboxy terminal amino acids led to a stepwise
reduction of reporter gene activation (Fig. 1B, M1/369 and
M1/243). The finding that a construct harboring Rep amino
acids 172–243 scored negative seems to contrast the results
obtained with Rep68 and M172/530. However, the lack of a
detectable interaction may be due either to low expression
levels or improper folding of the rather small fusion protein.
A well-characterized point mutation in the nucleotide
binding of the Rep proteins, which abrogates their enzy-
matic activities, demonstrates that this motif is dispensable
for the interaction with UBC9 (Fig. 1B, Rep68K340H).
For the analysis of the UBC9 regions involved in the
interaction with Rep, we chose the Rep M1/481 construct as
a binding partner because it showed the strongest reporter
gene activation with wild type UBC9 (compare Fig. 1B).
Already small deletions from either the amino terminus or
the carboxy terminus of full-length UBC9 led to an
abolishment or a dramatic decrease in the strength of
Fig. 1. Identification of UBC9 as a Rep-interacting protein. (A) Schematic representation of the AAV2 genome, the Rep68 and Rep40 proteins and the Rep
deletion mutant M172/530 used as bait in the yeast two-hybrid-screen. The inverted terminal repeats (ITRs) are represented by hatched boxes, the three
promoters at map units 5, 19, and 40 are indicated by right-angled arrows and the common polyadenylation (polyA) site for all transcripts at map position 96 is
indicated by the vertical arrow. Closed and differently shaded boxes indicate the Rep78/Rep68 specific region, the region common to all 4 Rep proteins and the
Rep68/Rep40 specific region. Characteristic amino acid positions are given above the boxes. (B) Analysis of Rep domains required for interaction with full-
length UBC9 in the yeast two-hybrid system. The Rep regions fused to the Gal4 DNA binding domain are shown schematically on the left and indicated by
amino acid numbers. The respective h-galactosidase (h-gal) activities expressed in Units are shown on the right and are corrected for the values obtained in
control cotransformations of the respective Rep constructs with pGAD424, which were all below 1.0 Unit. (C) Analysis of UBC9 domains required for
interaction with Rep-M1/481 in the yeast two-hybrid system. The UBC9 regions fused to the Gal4 transactivation domain are shown schematically on the left
and indicated by amino acid numbers. The respective h-gal activities expressed in units are shown on the right and are corrected for the values obtained in
control cotransformations of the respective UBC9 constructs with pGBT9, which were all below 1.0 h-gal Units. (B, C) The mean and standard deviation are
presented for at least four assays performed with independent transformants.
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UBC9 as a SUMO-conjugating enzyme relies on the active
site cysteine residue at amino acid position 93 (Tong et al.,
1997), which is engaged in thioester formation with the
carboxy group of a terminal glycine residue of the SUMO
proteins generated by proteolytic cleavage (Mahajan et al.,
1998). Point mutation of this active site cysteine residue to
serine did not affect the interaction with Rep (Fig. 1C,
UBC9C93S). Thus, the Rep–UBC9 interaction is independ-
ent of UBC-SUMO thioester formation.
In vitro binding of 35S-labeled Rep78 to a GST-UBC9 fusion
protein
To confirm that the Rep–UBC9 interaction detected in
the yeast two-hybrid system was due to a direct binding of
Rep to UBC9, GST pulldown assays with in vitro tran-
scribed/translated Rep proteins were performed. While
Rep78 specifically bound to a GST fusion protein of full-
length UBC9 (Fig. 2, upper panel), the corresponding small
Rep52 protein showed no binding (Fig. 2, lower panel).
These findings correspond to the results obtained in the
yeast two-hybrid analysis.
Rep78 and Rep68 can be covalently modified by SUMO-1
Since UBC9 functions as a SUMO E2 conjugating
enzyme, we examined a possible SUMO-1 modification ofFig. 2. Binding of 35S-labeled Rep78 to a GST–UBC9 fusion protein in
vitro. Rep78 (upper panel) or Rep52 (lower panel) were transcribed/
translated in vitro in the presence of 35S-methionine. Equal amounts of
labeled proteins were incubated with either GST protein alone or a GST/
full-length UBC9 fusion protein. Bound proteins were analyzed by SDS-
PAGE with subsequent autoradiography. The lane marked binputQ depicts
the amount of labeled Rep proteins used in the pull-down assay.the large AAV-2 Rep proteins Rep78 and Rep68. For this
purpose, Rep expression constructs were transfected into
HeLa cells together with a YFP (yellow fluorescent protein)
tagged SUMO-1 fusion protein. As a control, cells were
cotransfected with the Rep expression constructs and a
construct encoding the YFP protein only. Cell extracts were
prepared under denaturing conditions and subjected to
Western blot analysis with a monoclonal anti-Rep antibody.
After coexpression of Rep78 or Rep68 with the YFP-tagged
SUMO-1 protein, additional Rep isoforms at 120 or 110
kDa, respectively, could be detected (Fig. 3A, lanes 4 and
6). These Rep isoforms, which were not observed in the
control transfections of the large Rep proteins together with
the YFP protein (Fig. 3A, lanes 3 and 5), are consistent with
a covalent modification of the respective Rep protein by a
single YFP-SUMO-1 moiety, which has a size of 40 kDa.
Several low-molecular-weight bands probably representing
degradation products of Rep78 or Rep68 were detected in
all Rep-expressing cell lysates, regardless of the presence or
absence of YFP-SUMO (Fig. 3A, lanes 3–6). No Rep
reactive bands were detected in control cells expressing YFP
(Fig. 3A, lane 1) or YFP-SUMO-1 (Fig. 3A, lane 2)
excluding the possibility of a cross-reaction of the Rep
antibody with cellular proteins. To confirm that the bands at
120 and 110 kDa did indeed correspond to YFP-SUMO-1
modified Rep proteins, whole cell extracts of HeLa cells
transfected as described above were subjected to immuno-
precipitation with a Rep-antiserum. Immunoprecipitates
were subsequently analyzed for YFP-SUMO-1 conjugates
of Rep78 and Rep68 by Western analysis using an anti-YFP
antibody (Fig. 3B). YFP reactive bands at 120 or 110 kDa
corresponding in size to the bands observed in the anti-Rep
Western could be detected after coexpression of Rep78 and
Rep68 with YFP-SUMO-1 (Fig. 3B, lanes 4 and 6). These
bands were not observed in the absence of YFP-SUMO-1
(Fig. 3B, lanes 3 and 5) or Rep protein expression (Fig. 3B,
lanes 1 and 2). These experiments clearly demonstrate that
an exogenous SUMO-1 protein can covalently modify both
Rep78 and Rep 68.
Rep lysine residue 84 is the major acceptor site for SUMO-1
modification
An acceptor consensus sequence aKX(E,D), where bKQ is
the modified lysine residue and baQ represents a large
hydrophobic amino acid, has been depicted from the
analysis of the acceptor sites in a variety of SUMO-1 target
proteins (Melchior, 2000). No KXD motif is present within
the open reading frames of Rep78 or Rep68, whereas both
proteins share three common KXE motifs. These KXE
motifs are located at Rep78/Rep68 amino acid positions 84,
447, and 463 (Fig. 4A). Only the lysine residue at amino
acid position 447 is directly preceded by a hydrophobic
amino acid. To identify the Rep SUMO-1 acceptor site,
lysine residues 84, 447, and 463 were mutated to arginine
residues, either individually or in various combinations. The
Fig. 4. Mapping of the SUMO-1 attachment site of Rep78. (A) Sequence
alignment of the minimal sumolation consensus motif and the three KXE
motifs found in the Rep78 reading frame. (B, C) Analysis of SUMO-1
modification of wild-type Rep78 protein and different Rep78 lysine to
arginine point mutants. HeLa cells were cotransfected with the respective
pKEXRep78 expression construct, pKEX-UBC9 expressing full-length
UBC9 under control of the HCMV promoter, and either the YFP (lanes
marked bQ) or the YFP-SUMO-1 expression construct (lanes marked b+Q).
Whole cell extracts were analyzed by immunoblotting with the monoclonal
Rep antibody 303.9. Arrows indicate unmodified and YFP-SUMO-1
modified forms of the Rep78 proteins.
Fig. 3. Rep78 and Rep68 can be covalently modified by SUMO-1. (A, B)
HeLa cells were cotransfected with pEYFP-SUMO encoding an YFP-
SUMO-1 fusion protein and Rep expression plasmids pKEXRep78 or
pKEXRep68 as indicated. As controls (lanes marked bQ), pEYFP-C2
encoding the YFP protein or the empty expression vector pKEX,
respectively, were cotransfected. Filled dots indicate YFP-SUMO-1
modified forms of Rep78 and Rep68. (A) Unmodified and YFP-SUMO-
1-modified forms of the Rep proteins in whole cell extracts were analyzed
by immunoblotting with the monoclonal Rep antibody 303.9. (B) Whole
cell extracts were subjected to immunoprecipitation with a polyclonal anti-
Rep antiserum and precipitated proteins were analyzed by immunoblotting
with an anti-GFP polyclonal rabbit antibody, which is also reactive with the
YFP protein. The left-handed arrow indicates the position of the IgG heavy
chains of the Rep-antiserum used for the immunoprecipitation.
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basic charged residue at the respective amino acid position.
The mutant Rep78 proteins were then analyzed for SUMO-1
conjugation after coexpression with the YFP-tagged
SUMO-1 protein as described above. Both the K447R
mutant and the K463R mutant could still be conjugated with
YFP-SUMO-1 to a similar extent as the wild-type Rep78
protein (Fig. 4B, compare lanes 2, 6, and 8). In contrast,
modification by YFP-SUMO-1 was almost completely
abolished for the K84R mutant (Fig. 4B, lane 4). In line
with this finding, a strong reduction in sumolation was also
observed for the K84R/K447R double mutant (Fig. 4C, lane
4) and no sumolation was detected for the triple mutant with
all three lysine residues mutated to arginine (Fig. 4C, lane
6). These experiments identify Rep amino acid 84 as the
major acceptor site for SUMO-1 modification. The lysine
residue at amino acid position 84 is not directly preceded bya hydrophobic amino acid and thus does not seem to fit into
the sumolation consensus sequence. However, three phenyl-
alanine residues and one valine residue are found in amino
acid positions 2 to 6 with respect to this lysine residue
(Fig. 4A).
Influence of SUMO-1 modification on Rep78 protein
stability
SUMO-1 modification has been implicated in the
regulation of protein–protein interactions, of protein stabil-
ity, and in the determination of the intracellular localization
of the respective target protein (Melchior, 2000). When we
examined the intracellular localization of the largely
sumolation-deficient Rep78 K84R mutant in comparison
to the wild-type protein by immunofluorescence analysis,
we observed no differences between the two proteins. Either
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exclusion of nucleoli (data not shown). A possible
contribution of SUMO-1 modification to Rep78 protein
stability was examined in pulse-chase experiments. HeLa
cells transfected with wild-type Rep78 or the Rep78-K84R
mutant were labeled with 35S-methionine and 35S-cysteine
for a 2-h pulse from 22 to 24 h post transfection and cells
were chased for 2, 12, 24, or 36 h. No difference was
observed in the synthesis of the wild-type Rep78 protein
and the K84R mutant during the initial labeling period
(Figs. 5A, B, 0 h). Thus, differential autoregulatory effects
of the two Rep proteins on the CMV promoter driving their
expression or major differences in translation efficiencies
can be excluded. While the amount of labeled Rep78 wild-
type protein showed only a minor, about two-fold decrease
over a 24-h time period (Fig. 6B), a 20-fold reduction in the
amount of labeled K84R-Rep78 protein was observed over
the same time period. The respective half-lives were
calculated to 14.5 h for the wild-type Rep78 protein
compared to only 4.7 h for the mutant Rep78-K84R protein.Fig. 5. Determination of the stability of the wild-type Rep78 protein and the
largely sumolation-deficient Rep78-K84R mutant by pulse-chase experi-
ments. (A) Rep78 and Rep78-K84R were transfected into HeLa cells and
cells were labeled with 35S methionine and 35S cysteine for a 2-h pulse from
22 to 24 h post transfection. Cells were chased with medium containing
nonlabeled amino acids for the indicated time periods. Rep proteins were
immunoprecipitated with a polyclonal anti-Rep antibody and subjected to
SDS-PAGE followed by autoradiography. (B) Quantification of the pulse-
chase experiment shown in (A) by phosphoimager analysis of the dried
SDS-PAGE gel with the Image Quant software (Molecular Dynamics).
Boxes held in black indicate the wild-type Rep78 protein, while triangles
held in gray refer to Rep78-K84R.Sumolation of the large AAV Rep proteins is not required for
productive AAV replication
Since sumolation obviously is involved in the regulation
of Rep78 protein stability, we wondered whether this
modification is essential for the productive replication cycle
of AAV-2 in the presence of helpervirus. To address this
question, a mutant AAV genome carrying the lysine to
arginine point mutation at amino acid position 84 of the Rep
proteins in a plasmid backbone was generated (pTAV-
K84R). pTAV-K84R and the corresponding wild-type AAV
plasmid (pTAV2-0) were transfected into HeLa cells, which
were subsequently infected with adenovirus type 2 (Ad2) at
a multiplicity of infection (MOI) of 10. Expression of Rep
and Cap proteins was monitored in Western blot analysis at
18, 26, 40, or 50 h post infection. In parallel, AAV DNA
replication was assayed at 18 or 26 h post infection and the
amount of infectious AAV particles was determined at 20,
32, or 44 h post infection. Mutating the SUMO-1 acceptor
site had no major effect on accumulation of Rep and Cap
proteins (Fig. 6A) or on AAV DNA replication (Fig. 6B).
The mutant AAV genome also generated similar amounts of
AAV particles as the wild type AAV genome. At no time
point after transfection did the titer of infectious virus
obtained for AAV wild type exceed that obtained for the
mutant virus by more than one log (Fig. 6C). Similar results
were obtained when the corresponding virus preparations
were used for reinfection of new cells at equal MOIs (data
not shown). These data show that the stability of the Rep78
protein does not limit productive AAV replication in cell
culture in the presence of adenovirus as a helper.Discussion
The large Rep proteins Rep78 and Rep68 of AAV-2 are
multifunctional proteins that are essential for AAV DNA
replication and regulation of AAV gene expression (Berns,
1990; Carter et al., 1990). Using a yeast-based two-hybrid
system, we have identified UBC9, the conjugating enzyme
for the SUMO family of ubiquitin-related polypeptides, as
an interaction partner of the large Rep proteins. Direct
binding of UBC9 to Rep78 was confirmed by an in vitro
binding assay. We could demonstrate that Rep78 and Rep68
are subject to SUMO-1 modification with the lysine residue
at Rep amino acid position 84 as the main acceptor site. A
largely sumolation-deficient Rep78 mutant exhibits a
strongly reduced half-life, implicating SUMO-1 modifica-
tion in the regulation of Rep protein stability.
UBC9 physically interacts with various cellular and viral
proteins and mediates the attachment of SUMO-1 to one or
more lysine residues in the target protein (Johnson and
Blobel, 1997). In analogy to the ubiquitin system, several
SUMO-1 E3 ligases that enhance the sumolation of specific
substrates have been identified recently (Pichler et al., 2002;
Sachdev et al., 2001). Although UBC9-mediated alterations
Fig. 6. Replication of a mutant AAV genome harboring a lysine to arginine point mutation at amino acid position 84 of the large Rep proteins. (A–C) HeLa
cells were transfected either with the AAV wild-type plasmid pTAV2-0 (wt) or with plasmid pTAV2K84R (mu) carrying the lysine to arginine point mutation
and overinfected with adenovirus type 2 at an MOI of 10. At the indicated time points post infection, cells were monitored (A) for Rep and Cap expression by
immunoblot analysis with monoclonal antibodies 303.9 and B1, respectively, (B) for AAV DNA replication by Southern blot analysis and (C) for production of
infectious virions by dot blot analysis.
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ent of sumolation have also been reported for a small subset
of UBC9 binding proteins (Hahn et al., 1997; Kurtzman and
Schechter, 2001; Poukka et al., 1999), most of the UBC9-
interacting proteins have subsequently been identified as
targets for SUMO modification (Melchior, 2000). In line
with the function of UBC9 as a SUMO-1-conjugating
enzyme, Rep isoforms corresponding in size to the addition
of a single SUMO-1 moiety could be detected after
coexpression of an exogeneous YFP-tagged SUMO-1
protein both in Western blot analysis and in immunopreci-
pitation. The denaturing conditions that were employed in
these experiments confirm the covalent nature of the
interaction. Only a small fraction of the total amount of
the large Rep proteins was found to be posttranslationally
modified by SUMO-1. The same phenomenon has also been
observed for many other SUMO-1 target proteins like the
tumor suppressor protein p53 (Gostissa et al., 1999;
Rodriguez et al., 1999) or the transcription factor Sp3 (Ross
et al., 2002; Sapetschnig et al., 2002). Sumolation is a
reversible modification and the actual proportion of the
sumolated form of the respective target protein may depend
upon the relative activities of the enzymes involved in
SUMO conjugation and SUMO specific isopeptidases,
which have been found in a variety of cellular compartments(Gong et al., 2000; Kim et al., 2000; Nishida et al., 2000).
Alternatively, only a subpopulation of the large Rep
proteins, which fulfills specific functions within the cell,
may be subject to sumolation. These possibilities are not
mutually exclusive. The SUMO-1 modification of the large
Rep proteins observed after transient expression of both
proteins raises the question whether Rep78 and Rep68 are
also modified by endogenous SUMO-1 after coinfection of
cells with AAV-2 and helpervirus. Although we observed
some anti-Rep reactive protein bands migrating slower than
the major Rep78 and Rep68 bands after AAV-2/adenovirus
coinfection, we were not able to definitely prove that these
bands correspond to SUMO-1-modified forms of the large
Rep proteins (data not shown). The levels of exogenous
YFP-SUMO-1 obtained after cotransfection of the CMV-
driven expression construct are probably quite high as
compared to the level of endogenous SUMO-1 protein,
which may lead to an overstatement of the fraction of the
Rep proteins actually modified by SUMO-1 under physio-
logical conditions. In line with this argumentation, we favor
the possibility that modification of the AAV Rep proteins by
endogenous SUMO-1 may be below the detection limits of
the commonly available SUMO-1 antibodies.
The major SUMO-1 lysine acceptor residue is located in
the N-terminal region of Rep78/Rep68 at amino acid
S. Weger et al. / Virology 330 (2004) 284–294 291position 84. Some residual modification was seen after point
mutation of this lysine residue to arginine, which may point
to the presence of additional, alternative acceptor sites.
Similar findings have been made with p53, c-Jun (Schmidt
and Muller, 2002), TEL (Chakrabarti et al., 2000), and
Sp100 (Pichler et al., 2002). Rep lysine residue 447 may be
one candidate for an alternative acceptor site, since point
mutation of this lysine residue further reduced sumolation.
From a variety of SUMO-1 target protein, a sumolation
consensus site, cKxE (where c represents a large hydro-
phobic amino acid), has been depicted (Hay, 2001;
Melchior, 2000). Whereas the amino acids surrounding
Rep lysine residue 447 fit into the sumolation consensus
sequence, those surrounding the major Rep sumolation site
at lysine residue 84 do not. However, nonconsensus SUMO-
1 acceptor sites have also been reported from other target
proteins (Hoege et al., 2002; Kagey et al., 2003; Kim et al.,
1999). Of note, a total of four hydrophobic amino acids are
found at position 2 to 6 with respect to Rep amino acid
84, which may compensate for the lack of a hydrophobic
amino acid at position 1.
Whereas the intracellular localization of the largely
sumolation-deficient Rep78-K84R mutant was not altered,
it showed a markedly reduced half-life as compared to the
wild-type Rep78 protein. The mechanisms underlying the
regulation of the stability of the large Rep proteins by
SUMO-1 modification remain to be elucidated. For the
inhibitor protein InB, which sequesters the transcription
factor NFnB in the cytoplasm, a competition of sumolation
and ubiquitination for the same lysine residue was demon-
strated (Desterro et al., 1998). By this mechanism, SUMO-1
modification prevents polyubiquitination and subsequent
proteasome-mediated degradation of InB. Nothing is known
yet about polyubiquitination of the large Rep proteins.
However, our results confirm those of earlier studies
(Redemann et al., 1989) that the AAV-2 Rep proteins are
rather long-lived proteins and probably do not undergo
extensive polyubiquitination. An AAV genome harboring
largely sumolation-deficient Rep78/Rep68 proteins was
clearly not impaired for productive AAV infection in cell
culture in the presence of adenovirus. This was not an
unexpected finding since it has been shown that the
concentration of the large Rep proteins is not the limiting
factor for AAV replication (Weger et al., 1997). On the
contrary, a modest reduction in the levels of the large Rep
proteins may even enhance AAV DNA replication and
capsid protein expression (Li et al., 1997). Concerning the
importance of Rep sumolation for the AAV life cycle, one
may speculate that the stability of large Rep proteins plays a
role in the maintenance of the latent state of AAV in the
absence of helpervirus. During AAV latency in cell culture,
only a very low expression of AAV genes can be detected
(Laughlin et al., 1986; Walz and Schlehofer, 1992). This low
expression level is most probably due to down regulation of
all three AAV promoters by the large Rep proteins (Horer et
al., 1995; Kyostio et al., 1994). Rep78/Rep68-mediateddown-regulation of the p5 promoter creates a negative
autoregulatory feedback loop, which limits the expression
of the large Rep proteins. It has been shown that the large
Rep proteins exert cytostatic effects already at modest
concentrations (Yang et al., 1994). Thus, high Rep protein
stability may be important to ensure continuous down-
regulation of AAV gene expression during latency without a
transient increase in the levels of the large Rep proteins.Materials and methods
Plasmids
The yeast two-hybrid expression constructs encoding
fusions of the Gal4 DNA-binding domain with various parts
of the Rep open reading frame have been described (Weger
et al., 1999, 2002). Plasmid pGAD424-UBC9 (1–158)
encoding a fusion protein of the Gal4 transactivation
domain with full-length UBC9 corresponds to one of the
original clones obtained in the yeast two-hybrid screen for
Rep interacting protein. All other UBC9 two-hybrid
constructs were obtained from pGAD424-UBC9 (1–158)
through PCR amplification of the indicated parts of the
UBC9 coding region or by site-directed mutagenesis
(QuikChange Site-Directed Mutagenesis Kit, Stratagene).
The GST-UB9 expression vector pGEX-UBC9 was
obtained by subcloning of the UBC9 coding region and 3V
nontranslated region from pGAD24-UBC9 (1–158) into
plasmid pGEX-4T-3 (Promega).
Plasmids pKEXRep78 and pKEXRep68 expressing
AAV-2 Rep78 or Rep68, respectively, under control of the
human cytomegalovirus early promoter and plasmid
pEYFP-SUMO-1 expressing a fusion protein of the yellow
fluorescent protein with the complete open reading frame of
SUMO-1 have been described (Horer et al., 1995; Weger et
al., 2003). Plasmids pKEXRep78-K84R, pKEXRep78-
K447R, pKEXRep78-K463R, pKEXRep78K447/463R,
pKEXRep78K84/447R, and pKEXRep78K84/447/463R,
which harbor point mutations leading to a substitution of
lysine to arginine at the respective amino acid position, were
generated by site-directed mutagenesis from pKEX-Rep78,
while plasmid pTAV-K84R was generated by site-directed
mutagenesis from pTAV2-0.
All the expression vectors generated by PCR based
cloning or by site-directed mutagenesis were sequenced to
confirm that the inserted or mutated sequences were correct.
Yeast two-hybrid screening and analysis
A Gal4-based yeast two-hybrid screening system (Clon-
tech) was used to isolate cDNAs, which encode proteins that
are able to interact with the central part of the AAV-2 large
Rep proteins. Yeast two-hybrid screening of a cDNA library
from noninfected HeLa cells was performed essentially as
described in Weger et al. (1999) using HF7c yeast cells.
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in yeast strain SFY526 (Clontech) as described in Weger et
al. (2003).
GST pull-down assays
GST pull-down assays with a GST-UBC9 fusion
protein and 35S labeled Rep78 and Rep52 were
performed as described in Weger et al. (1999). Bound
Rep proteins were eluted with SDS sample buffer, loaded
on a 10% polyacrylamide gel (SDS-PAGE) and visual-
ized by autoradiography.
Immunoprecipitation and Western blot analysis
HeLa cells transfected with the indicated expression
constructs were lysed directly in the culture dishes with
1 ml RIPA buffer (50 mM Tris–HCl pH 8.0, 150 mM NaCl,
0.5% DOC, 0.1% SDS and 1% NP40) containing 10 mM
iodoacetamide at 4 8C for 10 min. Lysates were clarified by
15 min centrifugation at 20,800  g and 4 8C. The
supernatant was incubated with a polyclonal anti-Rep
antiserum from guinea pig and subsequently 30 Al Protein
A Sepharose beads in RIPA buffer (10%, w/v) were added for
1 h at 4 8C. Beads were washed five times with RIPA buffer
containing 10 mM iodoacetamide. Immunoprecipitated
proteins were analyzed by Western blot using a polyclonal
anti-GFP antiserum from goat (Biotrend, Kfln, Germany).
Pulse-chase analysis
Transfected cells were metabolically labeled with 50 ACi
of 35S-methionine and 35S-cysteine (in vitro cell labeling
mix, Amersham) for 2 h. Labeling medium was removed
and cells were washed three times with 1 ml of DMEM
containing unlabeled methionine and cysteine. After further
incubation for the indicated time periods, cells were
harvested in 1 ml RIPA buffer and subjected to immuno-
precipitation with an anti-Rep antiserum as described above.
Immunoprecipitated Rep proteins were analyzed by SDS-
PAGE and subsequent autoradiography.
Extraction of viral DNA and Southern blotting
Extraction of viral DNA by a modified Hirt procedure
and Southern blotting were performed as described in Weger
et al. (1997). After treatment with DpnI to digest input
DNA, the DpnI-resistant replicated AAV-DNAs were
detected with a 1.59-kb 32P labeled HincII fragment from
plasmid pTAV2-0 (Heilbronn et al., 1990) harboring a large
part of the cap open reading frame.
Dot blot analysis of infectious AAV virions
Cells transfected with infectious AAV genomes and
overinfected with adenovirus type 2 (MOI= 10) were lysedby three freeze–thaw cycles. Cellular debris was removed
by centrifugation for 10 min at 5000 g and 4 8C and the
supernatant was incubated for 1 h at 56 8C to inactivate the
adenovirus. HeLa cells in 96-well plates (1  104 cells/well)
were infected with 10 Al each of serial dilutions of the
supernatants and coinfected with adenovirus type 2 (MOI =
10). After 3 days, cells were subjected to three freeze–thaw
cycles, transferred to a nylon membrane, and hybridized
with the 1.59-kb 32P labeled HincII pTAV2-0 fragment
described above.Acknowledgment
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